Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Radioactivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Radioactivity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-004979-39 Sponsor Protocol Number: MSP-2017-1220 Start Date*: 2020-08-06
    Sponsor Name:Milestone Pharmaceuticals Inc.
    Full Title: An open-label, mass balance study to investigate the absorption, distribution, metabolism and excretion of [14C]-etripamil nasal spray after a single dose to healthy male subjects
    Medical condition: Paroxysmal supraventricular tachycardia (PSVT)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003495-39 Sponsor Protocol Number: Debio-0932-102 Start Date*: 2012-10-08
    Sponsor Name:Debiopharm SA
    Full Title: A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Sub...
    Medical condition: Debio-0932 is currently under development for the treatment of cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000267-17 Sponsor Protocol Number: VPI-103-01 Start Date*: 2007-02-21
    Sponsor Name:Verus Pharmaceuticals Inc
    Full Title: A SINGLE CENTRE, GAMMA SCINTIGRAPHY STUDY IN ASTHMATIC PATIENTS TO COMPARE PULMONARY DEPOSITION AND PHARMACOKINETICS OF ALBUTEROL INHALATION SOLUTION (AIS) DELIVERED VIA eFLOW NEBULISER AND SALBUTA...
    Medical condition: The medical condition which is under investigation is Asthma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004928-39 Sponsor Protocol Number: D-FR-01070-002 Start Date*: 2017-11-23
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, randomised, dose-confirmation, factorial phase II study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in subjects with gastroenteropancreatic neuroendocrine tumo...
    Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000040-30 Sponsor Protocol Number: 202100912 Start Date*: 2023-03-06
    Sponsor Name:University Medical Center Groningen
    Full Title: An open label pilot study of [18AlF]-Resca-IL2 (Interleukin-2 PET tracer) for positron emission tomography imaging in patients treated with immune checkpoint inhibitors.
    Medical condition: patients with stage IV non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), CSCC, urothelial cell cancer (UCC), and head and neck squamous cell carcinoma (HNSCC), eligible for ICI the...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003898-26 Sponsor Protocol Number: 516-007 Start Date*: 2019-12-23
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE MASS BALANCE, ROUTE OF ELIMINATION, AND METABOLIC PROFILE OF [14C] LABELED MGCD516 MALATE SALT IN HEALTHY MALE SUBJECTS
    Medical condition: Cancer/oncology
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003461-96 Sponsor Protocol Number: AGO/2017/006 Start Date*: 2017-12-21
    Sponsor Name:Ghent University Hospital
    Full Title: PSMA-PET/CT for prostate cancer
    Medical condition: prostate cancer (and metastases)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003137-42 Sponsor Protocol Number: EPIFLUX Start Date*: 2020-04-10
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Exploring P-glycoprotein-mediated efflux transport at the blood-brain barrier as a biomarker of drug-resistance in focal epilepsy
    Medical condition: Investigation in healthy volunteers and epilepsy patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004802-70 Sponsor Protocol Number: APHP200491 Start Date*: 2021-08-03
    Sponsor Name:Assistance Publique – Hôpitaux de Paris
    Full Title: Impact of post-ARDS COVID sedation on late neuroinflammation
    Medical condition: All patients who have developed and survived ARDS linked to COVID-19 infection, admitted to intensive care units, meeting the study's inclusion criteria may be included in this research.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004727-37 Sponsor Protocol Number: CAAA603A12101 Start Date*: 2019-02-18
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with...
    Medical condition: Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004878-28 Sponsor Protocol Number: dipy001 Start Date*: 2006-12-27
    Sponsor Name:UMCN farm-tox
    Full Title: Does caffeine reduce dipyridamole-induced protection against ischemia-reperfusion injury?
    Medical condition: Reperfusion after an ischemic accident will limit tissue damage (infacrt size), though on the other hand reperfusion injury will also cause tissue damage by the release of ROS and facilitating cell...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062828 Ischemic heart disease prophylaxis LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000033-36 Sponsor Protocol Number: LYMRIT-37-01 Start Date*: 2012-10-18
    Sponsor Name:Nordic Nanovector ASA
    Full Title: A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.
    Medical condition: Non-Hodgkin B-cell lymphoma Part A: Relapsed indolent Non-Hodgkin B-cell lymphoma Part B: Relapsed follicular lymphoma Part C: Relapsed indolent Non-Hodgkin B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) FR (Ongoing) ES (Prematurely Ended) HR (Completed) HU (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed) DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002341-35 Sponsor Protocol Number: GA1103 Start Date*: 2011-07-21
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A randomised single dose two cohort study comparing the speed of raft formation assessed by gamma scintigraphy in healthy volunteers following administration of a single dose of Gaviscon® Strawberr...
    Medical condition: To measure the formation and retention of alginate rafts in healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002867-41 Sponsor Protocol Number: OPS-C-001/D-FR-01072-001 Start Date*: 2015-12-10
    Sponsor Name:Ipsen Pharma
    Full Title: An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor positi...
    Medical condition: Neuroendocrine tumors (NETs)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002085-31 Sponsor Protocol Number: RAD-ON02 Start Date*: 2017-11-14
    Sponsor Name:Kurort Forschungsverein Bad Steben e.V.
    Full Title: Determining the immunological and pain reducing effects of serial radon balneology in patients with musculoskeletal disorders.
    Medical condition: Chronic degenerative spine and/or joint disorders with pain perception of at least 1 year and pain intensity on visual analogue scale ≥4
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006706-29 Sponsor Protocol Number: 01 Start Date*: 2007-02-12
    Sponsor Name:UMCN department Pharm-Tox
    Full Title: Does atorvastatin reduce ischemia-reperfusion injury in humans in-vivo?
    Medical condition: ischemia reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028596 Myocardial infarction LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005789-11 Sponsor Protocol Number: atorv02 Start Date*: 2008-03-11
    Sponsor Name:RUNMC
    Full Title: Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo?
    Medical condition: ischemia-reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023033 Ischemia myocardial LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005893-29 Sponsor Protocol Number: atp01 Start Date*: 2008-08-14
    Sponsor Name:RUNMC
    Full Title: Does ATP cause Annexin A5 targeting in the human forearm?
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002822-28 Sponsor Protocol Number: 11034 Start Date*: 2023-06-01
    Sponsor Name:University Medical Center Groningen, Department of Rheumatology and Clinical Immunology
    Full Title: CD8 T cell imaging by positron emission tomography with 89Zr-Df-IAB22M2C in giant cell arteritis and rheumatoid arthritis: a pilot study
    Medical condition: giant cell arteritis and rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001593-18 Sponsor Protocol Number: 958 Start Date*: 2015-06-02
    Sponsor Name:Medizinische Universiät Wien
    Full Title: A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans
    Medical condition: Investigation in volunteers only
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA